Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Matrin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P. Anti-tumor immunity triggered by melphalan is potentiated by melanoma cell surface associated calreticulin. Cancer Res 2015; 75: 1603-1614. http://www.ncbi.nlm.nih.gov/pubmed/25762540
Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014; 28: 1163-1167. http://www.ncbi.nlm.nih.gov/pubmed/24492323
Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J. 5-Aza-2’-deoxycytidine potentiates antitumor immune response induced by photodynamic therapy. Eur J Cancer 2014; 50: 1370-1381. http://www.ncbi.nlm.nih.gov/pubmed/24559534
Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21: 26-38. http://www.ncbi.nlm.nih.gov/pubmed/23686135
Firczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska-Steifer E, Wachowska M, Glodkowska-Mrowka E, Korsak B, Winiarska M, Golab J. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis 2013; 4: e741. http://www.ncbi.nlm.nih.gov/pubmed/23887632
Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, Wachowska M, Roszczenko K, Miaczynska M, Chlebowska J, Basak GW, Golab J. Prenyl transferases regulate CD20 levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. J Biol Chem 2012; 287: 31983-31993. http://www.ncbi.nlm.nih.gov/pubmed/22843692
Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, Oleszczak B, Sinski M, Firczuk M, Bujnicki JM, Chlebowska J, Staruch AD, Glodkowska-Mrowka E, Kunikowska J, Krolicki L, Szablewski L, Gaciong Z, Koziak K, Jakobisiak M, Golab J, Nowis DA. Statins impair glucose uptake in tumor cells. Neoplasia 2012; 14: 311-323. http://www.ncbi.nlm.nih.gov/pubmed/22577346
Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJM, Annaert W, Golab J, de Witte P, Vandenabeele P, Agostinis P. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079. http://www.ncbi.nlm.nih.gov/pubmed/22252128
Klossowski S, Muchowicz A, Firczuk M, Świech M, Redzej A, Golab J, Ostaszewski R. Studies towards novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system. J Med Chem 2012; 55: 55-67. http://www.ncbi.nlm.nih.gov/pubmed/22128876
Agostinis P, Berg K, Foster TH, Girotti AW, Gollnick SO, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. Photodynamic therapy of cancer: an update CA: A Cancer J Clin 2011; 61: 250-281. http://www.ncbi.nlm.nih.gov/pubmed/21617154
Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factors Rev 2011; 22: 99-108. http://www.ncbi.nlm.nih.gov/pubmed/21531164
Bil J, Winiarska M, Nowis D, Bojarczuk K, Dabrowska-Iwanicka A, Basak GW, Sulek K, Marek J, Golab J. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood 2010; 115: 3745-3755. http://www.ncbi.nlm.nih.gov/pubmed/20200358
Nowis D, Maczewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski M, Wilczynski GM, Malinowska M, Bil J, Salwa P, Bugajski M, Wojcik C, Sinski M, Abramczyk P, Winiarska M, Dabrowska-Iwanickab A, Duszynski J, Jakobisiak M, Golab J. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010; 176: 2658-2668. http://www.ncbi.nlm.nih.gov/pubmed/20519734
Mroczkiewicz M, Winkler K, Nowis D, Placha G, Golab J, Ostaszewski R. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. J Med Chem 2010; 53: 1509-1518. http://www.ncbi.nlm.nih.gov/pubmed/20112914
Szokalska A, Makowski M, Nowis D, Wilczynski GM, Kujawa M, Wojcik C, Mlynarczuk-Bialy I, Salwa P, Bil J, Janowska S, Agostinis P, Verfaillie T, Bugajski M, Gietka J, Issat T, Glodkowska E, Mrowka P, Stoklosa T, Hamblin MR, Mroz P, Jakobisiak M, Golab J. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of ER stress and unfolded protein response. Cancer Res 2009; 69: 4235-4243. http://www.ncbi.nlm.nih.gov/pubmed/19435917
Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab J. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5: e64 (502-517). http://www.ncbi.nlm.nih.gov/pubmed/18366248
Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, Schmidt B, Umbreen S, Golab J, Ludwig A, Montag C, Wiebusch L, Hagemeier C, Schadendorf D, Kloetzel P.M., Seifert U. Combined effect of proteasome and calpain inhibition on cisplatin resistant human melanoma cells. Cancer Res 2006; 66: 4598-7605. http://www.ncbi.nlm.nih.gov/pubmed/16885359
Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Waś H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M, Golab J. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 2006; 25: 3365-3374. http://www.ncbi.nlm.nih.gov/pubmed/16462769
Jalili A, Makowski M, Świtaj T, Nowis N, Wilczynski GM, Wilczek E, Choraay-Massalska M, Radzikowska A, Maślinski W, Bialy L, Sienko J, Sieron A, Adamek M, Basak G, Mroz P, Krasnodębski IW, Jakobisiak M, Golab J. Effective photoimmunotherapy of murine colon carcinoma induced by the combinationn of photodynamic therapy and dendritic cells. Clin Cancer Res 2004; 10: 4498-4508. http://www.ncbi.nlm.nih.gov/pubmed/15240542
Świtaj T, Jalili A, Jakubowska AB, Drela N, Stoksik M, Nowis D, Basak G, Golab J, Wysocki PJ, Mackiewicz A, Sasor A, Socha-Urbanek K, Jakobisiak M, Lasek W. CpG immunostimulatory oligodeoxynucleotide (ODN) 1826 enhances antitumor effec of IL-12 gene-modified vaccine in a melanoma model in mice. Clin Cancer Res 2004; 10: 4165-4175. http://www.ncbi.nlm.nih.gov/pubmed/15217954
Makowski M, Grzela T, Niderla J, Lazarczyk M, Mroz P, Kopeć M, Legat M, Strusinska K, Koziak K, Nowis D, Mrowka P, Wasik M, Jakobisiak M, Golab J. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res 2003; 9: 5417-5422. http://www.ncbi.nlm.nih.gov/pubmed/14614028
Kozar K, Kaminski R, Świtaj T, Oldak T, Machaj E, Wysocki PJ, Mackiewicz A, Jakobisiak M, Golab J. Interleukin 12 based immunotherapy improves the antitumor effectiveness of a low-dose 5-aza-2‘-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 2003; 9: 3124-3133. http://www.ncbi.nlm.nih.gov/pubmed/12912964
Golab J, Nowis D, Skrzycki M, Czeczot H, Anna Baranczyk-Kuzma A, Wilczynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, Jalili A, Kopeć M, Grzela T, Jakobisiak M. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol - a superoxide dismutase inhibitor. J Biol Chem. 2003; 278: 407-414. http://www.ncbi.nlm.nih.gov/pubmed/12409296
Golab J, Olszewska D, Mroz P, Kozar K, Kaminski R, Jalili A, Jakobisiak M. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin Cancer Res 2002; 8: 1265-1270. http://www.ncbi.nlm.nih.gov/pubmed/12006547
Golab J, Zagoadaon R, Kaminski R, Kozar K, Gryska K, Iaycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W, Jakobisiak M. Potentiatied antitumor effectiveness of combined immuno-chemotherapy with interleukin-12 and 5-Fluorouracil of L1210 leukemia in vivo. Leukemia 2001; 15: 613-620. http://www.ncbi.nlm.nih.gov/pubmed/11368364
